Aehr Test Systems Wins $41 Million AI Order, Hits All-Time High
NEW YORK, May 9 —
Aehr Test Systems, Inc. just won a $41 million AI order worth nearly its entire annual revenue, sending shares to a record $102.71.
- $41mn order win drove AEHR to an all-time high of $102.71; shares last at $97.23
- 648.2x fwd P/E on $45mn TTM revenue. At that multiple, the stock is valued like a company several times its current size.
- Next data point: order backlog size and revenue guidance at the next earnings report
What Actually Happened
At $41 million, this order equals roughly 91% of Aehr's trailing twelve-month revenue of $45 million. That is not a routine contract win. It resets every forward revenue estimate. Aehr builds wafer-level burn-in and test systems — a niche that sits directly upstream of chip assembly and grows more critical as AI accelerators demand tighter reliability tolerances. The wire services missed the key detail: Aehr's AI exposure runs through none of the obvious channels — not software, not cloud, not chip design. It comes from the physics of stress-testing silicon before it ships to a hyperscaler. When AI capital expenditure rises, wafer test volumes rise with it. Aehr gets paid regardless of which chip architecture wins.
The Catch
A 648.2x forward P/E on $45mn in TTM revenue is not a valuation — it is a declaration of faith. The all-time high of $102.71 reflects momentum buying as much as any analyst upgrade cycle. One $41mn order confirms Aehr's position in AI test infrastructure. It does not resolve the arithmetic. Revenue guidance at the next earnings call will show whether this is the first win in a multi-year demand cycle or a single lumpy contract that leaves investors waiting for the pipeline to refill.
Bottom Line
Growth investors get a genuine AI infrastructure toll-road thesis. Aehr does not need to pick the winning model, GPU, or cloud platform. For value investors, 648x on $45mn in annual revenue is not a conversation. The one number that changes this story at the next earnings call is order backlog. If it grows beyond this $41mn win, estimate revisions follow and the multiple starts to compress. If the pipeline stalls, the stock is running on narrative at a price that assumes it never will.
For a full breakdown of Aehr Test Systems' financials, competitive position, and valuation, generate a Basis Report at /stock/aehr.
Basis Report does not hold positions in securities discussed. This is not investment advice.